Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Patent
1980-12-29
1984-02-14
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
548205, 548206, 548213, 548214, A61K 3144, C07D27502
Patent
active
044316526
ABSTRACT:
4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives of the formula: ##STR1## where X and Y are independently selected from the group consisting of hydrogen, halogen, and C.sub.1-6 alkyl; provided that positions 2 and 6 of the substituted phenyl moiety may not be substituted by C.sub.3-6 alkyl; or a pharmaceutically acceptable salt thereof;
useful in treating urinary tract, especially renal calcium oxalate lithiasis.
REFERENCES:
patent: 3849430 (1974-11-01), Lewis
patent: 4067878 (1978-01-01), Miller
patent: 4346094 (1982-08-01), Beck et al.
Cottet et al., "Is There Treatment for Calcium Nephrolithiasis?", Nouv. Presse Med. 5(3): 139-145 (1976).
Hautmann et al., "Calcium Oxylate . . . Disease . . . ", J. of Urology, pp. 712-715 (1978).
Randall et al., "Quantitative Structure . . . ," J. Med. Chem. 22:608 (1979).
Schwam et al., "Purification . . . Liver Glycolate . . . ", Biochemistry 13:2828-(1979).
Melon et al., "Experimental Oxalic Lithiasis . . . ," Therapie XXVI 991-998 (1971).
Thomas et al., "Traitement Hypooxalurigue . . . ," Therapie XXVI 999-1005 (1971).
Melon and Thomas, "Oxylate Nephrolithiasis . . . ", Agressologie 14(6): 357-365 (1973).
Thomas et al., "Succinate," J. d'Urologie et Nephrologie 80, No. 9 (1974).
Richardson, K. E., "Effect of Partial Hepatectomy . . . ", Toxicology and Pharmacology 24: 530-538 (1973).
J. Thomas, et al., "Recent Data on the Urinary Excretion . . . ", Ann. Urol. 6:(1): W 31-33 (1972).
Watts et al., ". . . Treatment . . . Hyperoxylurea . . . ," Quarterly J. of Med., (New Series) No. 190, pp. 259-272 (1978).
Scott et al, "Reduction in Urinary Oxylate . . . ", Urology, vol. 12: 212-214 (1978).
Smith, Lloyd, "Symposium on Stones," Amer. J. Medicine, pp. 649-653 (1968).
Williams, Hibbard et al., "Disorders of Oxylate Metabolism", Amer. J. Medicine, pp. 715-731 (1968).
Liao and Richardson, "Inhabition Oxalate Biosynthesis . . . ", Archives Biochem. and Biophysics 154: 68-75 (1972).
Liao and Richardson, "Metabolism Oxylate Precursers . . . ", Archives Biochemistry and Biophysics 153: 438-448 (1972).
Melon and Thomas, "Experimental Oxylate Lithiasis", Therapie 26: 985-990 (1971).
Lewis et al., J. Het. Chem., p. 591 (1971).
Burger, Medicinal Chemistry, p. 42.
Randall et al., J. Med. Chem., 22, p. 608.
Cragoe, Jr. Edward J.
Rooney Clarence S.
Williams Haydn W. R.
Arther Thomas E.
Daus Donald G.
Hendricks G.
Merck & Co. , Inc.
Merck Sharp & Dohme (I.A.) Corp.
LandOfFree
4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2374938